RxDoctor Payments Data

Ann Hughes Bass, MD

Family Medicine · Lubbock, TXNPI 1750736443

Payments from drug & device makers

$4,057in general payments, 2019–2025

Across 205 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$721
  • GSK$702
  • Novo Nordisk$604
  • AstraZeneca$423
  • Pfizer$270
  • Radius Health, Inc.$235
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,03199%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,057 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,068
Medicare patients
169
Services billed
1,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$204,982
OzempicSemaglutide63$75,306
JardianceEmpagliflozin42$66,332
FarxigaDapagliflozin Propanediol37$32,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,921
RybelsusSemaglutide15$29,202
EliquisApixaban17$24,928
Synjardy XrEmpagliflozin/Metformin Hcl14$16,835
TrulicityDulaglutide14$13,237
Estradiol45$3,615
Rosuvastatin Calcium193$2,291
Levothyroxine Sodium204$2,196
Gabapentin86$1,972
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$1,960
SynthroidLevothyroxine Sodium29$1,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$721$218,219188 claims
Novo NordiskOzempic, Rybelsus$604$104,50878 claims
AstraZenecaFarxiga$423$32,36737 claims
GSKTrelegy Ellipta$702$29,92135 claims
PfizerEliquis$270$24,92817 claims
AbbVieSynthroid$21$1,55629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →